![8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)]()
8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)Boerekamps, Anne; Vanwolleghem, Thomas; van der Valk, Marc; van den Berk, Guido E.; van Kasteren, Marjo; Posthouwer, Dirk; Dofferhoff, Anthonius S.M.; van Hoek, Bart; Ramsoekh, Dewkoemar; Koopsen, Jelle; Schinkel, Janke; Florence, Eric; Arends, Joop E.; Rijnders, Bart J. · Journal of Hepatology · 2018